Table 2 Analysis of contribution of in vitro parasite sensitivity and systemic drug exposure during acute phase of infection and relationship with pfmdr1 copy number in patients with sensitive response following treatment with a three-day artesunate (AS)-mefloquine (MQ) combination regimen

Adequate DHA exposure alone (n= 4)

18

2.90

Reduced (2.4±1.0)

Resistant (34.5±3.2)

>1

8.40^c

-Possible AS resistant

-MQ resistant + Inadequate MQ exposure

19

2.97

Sensitive (1.1±0.15)

Sensitive (8.0±1.4)

1

6.78^c

-AS sensitive

-MQ sensitive + Inadequate MQ exposure

-Predicted by pfmdr1 copy number

20

3.01

Sensitive (2.0±0.25)

Resistant (31.3±1.6)

1

7.77^c

- AS sensitive

- MQ resistant + Inadequate MQ exposure

-Predicted by pfmdr1 copy number

21

2.78

Sensitive (1.8±0.13)

Sensitive (17.5±3.0)

1

7.09^c

-AS sensitive

- MQ sensitive + Inadequate MQ exposure

-Predicted by pfmdr1 copy number

Adequate MQ exposure alone (n=9)

22

3.11

Reduced (3.2±0.15)

Resistant (90.0±16.5)

1

402^d

-Possible AS resistant + Inadequate DHA exposure

-MQ resistant

-Predicted by pfmdr1 copy number

23

3.23

Sensitive (0.4±0.04)

Sensitive (14.6±2.2)

1

389^d

-AS sensitive + Inadequate DHA exposure

-MQ sensitive

-Predicted by pfmdr1 copy number

24

2.78

Sensitive (0.3±0.10)

Sensitive (13.7±2.4)

1

390^d

-AS sensitive+ Inadequate DHA exposure

-MQ sensitive

-Predicted by pfmdr1 copy number

25

3.01

Sensitive (1.8±0.31)

Resistant (47.5±1.7)

>1

391^d

-AS sensitive + Inadequate DHA exposure

-MQ resistant

26

2.89

Sensitive (1.6±0.30)

Sensitive (20.9±0.5)

1

398^d

-AS sensitive+ Inadequate DHA exposure

-MQ sensitive

-Predicted by pfmdr1 copy number entration

27

2.77

Sensitive (1.6±0.24)

Resistant (27.1±1.0)

1

450^d

-Possible AS resistant + Inadequate DHA exposure

-MQ sensitive

-Predicted by pfmdr1 copy number

28

3.01

Sensitive (1.9±0.35)

Sensitive (18.5±2.4)

1

409^d

-AS sensitive + Inadequate DHA exposure

-MQ sensitive

-Predicted by pfmdr1 copy number

29

2.89

Sensitive (1.0±0.03)

Sensitive (8.1±0.1)

1

379^d

-AS sensitive + Inadequate DHA exposure

-MQ sensitive

-Predicted by pfmdr1 copy number

30

3.01

Sensitive (2.2±0.16)

Sensitive (19.1±1.0)

1

423^d

-AS sensitive + Inadequate DHA exposure

-MQ sensitive

-Predicted by pfmdr1 copy number

Adequate DHA and MQ exposure (n=6)

31

2.67

Reduced (3.4±0.44)

Resistant (100.7±16.8)

>1

-

-Possible AS resistant

-MQ resistant

32

2.89

Reduced (3.8±0.62)

Resistant (62.2±4.6)

>1

-

-Possible AS resistant

-MQ resistant

33

3.00

Reduced (3.3±0.37)

Resistant (60.0±4.2)

>1

-

-Possible AS resistant

-MQ resistant

34

3.00

Sensitive (1.4±0.31)

Sensitive (6.8±0.5)

1

-

-AS sensitive

-MQ sensitive

-Predicted by pfmdr1 copy number

35

2.09

Sensitive (0.9±0.13)

Resistant (25.1±0.2)

1

-

-AS sensitive

-MQ resistant

-Predicted by pfmdr1 copy number

36

2.89

Sensitive (1.6±0.19)

Sensitive (21.2±0.3)

1

-

-AS sensitive

-MQ sensitive

-Predicted by pfmdr1 copy number

Inadequate DHA and MQ exposure (n=2)

37

2.90

Sensitive (1.5±0.23)

Sensitive (14.3±2.7)

>1

5.34^c

-AS sensitive

234^d

-MQ sensitive

38

3.01

Sensitive (1.9±0.28)

Sensitive (22.1±0.4)

1

7.09^c

-AS sensitive

209^d

-MQ sensitive

-Predicted by pfmdr1 copy number